Sirnaomics Initiates Phase 2b Study Using STP705 for Treatment of Squamous Cell Skin Cancer

GAITHERSBURG, Md. and SUZHOU BIOBAY, China, April 25, 2021 /PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the initiation of the Phase 2b study of the...

from PR Newswire: https://ift.tt/3xqtXy4